annual CFF:
$36.17M+$37.78M(+2342.28%)Summary
- As of today (September 16, 2025), XERS annual cash flow from financing activities is $36.17 million, with the most recent change of +$37.78 million (+2342.28%) on December 31, 2024.
- During the last 3 years, XERS annual CFF has risen by +$8.92 million (+32.74%).
- XERS annual CFF is now -71.79% below its all-time high of $128.21 million, reached on December 31, 2018.
Performance
XERS Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$942.00K+$4.08M(+130.03%)Summary
- As of today (September 16, 2025), XERS quarterly cash flow from financing activities is $942.00 thousand, with the most recent change of +$4.08 million (+130.03%) on June 30, 2025.
- Over the past year, XERS quarterly CFF has increased by +$283.00 thousand (+42.94%).
- XERS quarterly CFF is now -98.96% below its all-time high of $90.80 million, reached on June 30, 2018.
Performance
XERS quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$1.88M+$283.00K(+13.08%)Summary
- As of today (September 16, 2025), XERS TTM cash flow from financing activities is -$1.88 million, with the most recent change of +$283.00 thousand (+13.08%) on June 30, 2025.
- Over the past year, XERS TTM CFF has dropped by -$36.43 million (-105.44%).
- XERS TTM CFF is now -101.17% below its all-time high of $160.16 million, reached on March 31, 2019.
Performance
XERS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
XERS Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2342.3% | +42.9% | -105.4% |
| 3 y3 years | +32.7% | +203.9% | -102.4% |
| 5 y5 years | -55.1% | -98.7% | -101.4% |
XERS Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -71.6% | +2342.3% | -98.1% | +130.0% | -101.5% | +13.1% |
| 5 y | 5-year | -71.6% | +2342.3% | -98.8% | +130.0% | -101.4% | +13.1% |
| alltime | all time | -71.8% | +2342.3% | -99.0% | +130.0% | -101.2% | +13.1% |
XERS Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $942.00K(-130.0%) | -$1.88M(-13.1%) |
| Mar 2025 | - | -$3.14M(-888.2%) | -$2.16M(-106.0%) |
| Dec 2024 | $36.17M(-2342.3%) | $398.00K(-579.5%) | $36.17M(+4.7%) |
| Sep 2024 | - | -$83.00K(-112.6%) | $34.54M(-0.0%) |
| Jun 2024 | - | $659.00K(-98.1%) | $34.55M(+0.3%) |
| Mar 2024 | - | $35.19M(-2952.0%) | $34.44M(-2235.4%) |
| Dec 2023 | -$1.61M(-101.3%) | -$1.23M(+1613.9%) | -$1.61M(-103.3%) |
| Sep 2023 | - | -$72.00K(-112.9%) | $48.78M(+0.2%) |
| Jun 2023 | - | $556.00K(-164.4%) | $48.66M(+0.5%) |
| Mar 2023 | - | -$863.00K(-101.8%) | $48.42M(-62.0%) |
| Dec 2022 | $127.47M(+367.8%) | $49.16M(<-9900.0%) | $127.47M(+62.5%) |
| Sep 2022 | - | -$187.00K(-160.3%) | $78.44M(-0.2%) |
| Jun 2022 | - | $310.00K(-99.6%) | $78.63M(-0.2%) |
| Mar 2022 | - | $78.19M(>+9900.0%) | $78.78M(+189.1%) |
| Dec 2021 | $27.25M | $125.00K(>+9900.0%) | $27.25M(-10.5%) |
| Sep 2021 | - | $1000.00(-99.8%) | $30.45M(-30.0%) |
| Jun 2021 | - | $460.00K(-98.3%) | $43.51M(-61.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | $26.66M(+701.6%) | $112.66M(-10.6%) |
| Dec 2020 | $126.06M(+56.5%) | $3.33M(-74.5%) | $126.06M(+1.1%) |
| Sep 2020 | - | $13.06M(-81.2%) | $124.71M(-7.1%) |
| Jun 2020 | - | $69.61M(+73.7%) | $134.22M(+108.2%) |
| Mar 2020 | - | $40.07M(+1933.9%) | $64.45M(-20.0%) |
| Dec 2019 | $80.53M(-37.2%) | $1.97M(-91.3%) | $80.53M(+2.5%) |
| Sep 2019 | - | $22.57M(<-9900.0%) | $78.59M(+13.6%) |
| Jun 2019 | - | -$157.00K(-100.3%) | $69.20M(-56.8%) |
| Mar 2019 | - | $56.15M(>+9900.0%) | $160.16M(+24.9%) |
| Dec 2018 | $128.21M(+264.9%) | $29.00K(-99.8%) | $128.21M(-4.1%) |
| Sep 2018 | - | $13.18M(-85.5%) | $133.65M(+10.9%) |
| Jun 2018 | - | $90.80M(+275.1%) | $120.48M(+305.8%) |
| Mar 2018 | - | $24.20M(+342.7%) | $29.69M(+480.1%) |
| Dec 2017 | $35.14M(+800.1%) | $5.47M(>+9900.0%) | $5.12M(-1566.5%) |
| Sep 2017 | - | $19.00K(-105.2%) | -$349.00K(-5.2%) |
| Mar 2017 | - | -$368.00K | -$368.00K |
| Dec 2016 | $3.90M | - | - |
FAQ
- What is Xeris Biopharma Holdings, Inc. annual cash flow from financing activities?
- What is the all time high annual CFF for Xeris Biopharma Holdings, Inc.?
- What is Xeris Biopharma Holdings, Inc. annual CFF year-on-year change?
- What is Xeris Biopharma Holdings, Inc. quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Xeris Biopharma Holdings, Inc.?
- What is Xeris Biopharma Holdings, Inc. quarterly CFF year-on-year change?
- What is Xeris Biopharma Holdings, Inc. TTM cash flow from financing activities?
- What is the all time high TTM CFF for Xeris Biopharma Holdings, Inc.?
- What is Xeris Biopharma Holdings, Inc. TTM CFF year-on-year change?
What is Xeris Biopharma Holdings, Inc. annual cash flow from financing activities?
The current annual CFF of XERS is $36.17M
What is the all time high annual CFF for Xeris Biopharma Holdings, Inc.?
Xeris Biopharma Holdings, Inc. all-time high annual cash flow from financing activities is $128.21M
What is Xeris Biopharma Holdings, Inc. annual CFF year-on-year change?
Over the past year, XERS annual cash flow from financing activities has changed by +$37.78M (+2342.28%)
What is Xeris Biopharma Holdings, Inc. quarterly cash flow from financing activities?
The current quarterly CFF of XERS is $942.00K
What is the all time high quarterly CFF for Xeris Biopharma Holdings, Inc.?
Xeris Biopharma Holdings, Inc. all-time high quarterly cash flow from financing activities is $90.80M
What is Xeris Biopharma Holdings, Inc. quarterly CFF year-on-year change?
Over the past year, XERS quarterly cash flow from financing activities has changed by +$283.00K (+42.94%)
What is Xeris Biopharma Holdings, Inc. TTM cash flow from financing activities?
The current TTM CFF of XERS is -$1.88M
What is the all time high TTM CFF for Xeris Biopharma Holdings, Inc.?
Xeris Biopharma Holdings, Inc. all-time high TTM cash flow from financing activities is $160.16M
What is Xeris Biopharma Holdings, Inc. TTM CFF year-on-year change?
Over the past year, XERS TTM cash flow from financing activities has changed by -$36.43M (-105.44%)